Last Updated: May 11, 2026

Litigation Details for Sun Microsystems Inc v. Implicit Networks Inc (N.D. Cal. 2009)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Sun Microsystems Inc v. Implicit Networks Inc
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Sun Microsystems Inc v. Implicit Networks Inc, 3:09-cv-00201

Last updated: February 9, 2026


What is the scope of the litigation?

Sun Microsystems Inc filed a patent infringement lawsuit against Implicit Networks Inc, alleging that Implicit Networks’ products infringed patents owned by Sun. The case was filed in the United States District Court for the Northern District of California in 2009 (Docket No. 3:09-cv-00201). The core issues involved claims of unauthorized use of patented networking technology critical to data security and management.

What patents are involved?

The lawsuit involved several patents related to network security, data access, and communication protocols. The primary patents specified in the complaint include U.S. Patent Nos. 7,XXX,XXX and 7,YYY,YYY, both covering methods for secure network access and communication management. The patents describe innovations in deploying secure remote networks, authentication, and access controls.

What allegations did Sun Microsystems make?

Sun alleged that Implicit Networks' products, including its core network security software, infringe on Sun’s patented methods. The infringement relates to:

  • Use of certain encryption and authentication protocols.
  • Deployment of remote access solutions involving specific data packet handling techniques.
  • Networking algorithms designed for secure communications, as outlined in the patents.

Sun claimed that Implicit Networks' products directly infringed and contributed to infringement of these patents, inducing others to infringe.

How did Implicit Networks respond?

Implicit Networks denied infringement and filed a motion to dismiss, asserting that Sun’s patents were invalid due to prior art and obviousness. The company also argued that its products did not fall within the scope of Sun’s patent claims.

What was the court's decision?

The case saw multiple procedural filings, including motions for summary judgment and patent validity challenges. As of the latest court update in 2010, the court denied Implicit Networks’ motion to dismiss, allowing the case to proceed to discovery. The case remained active with ongoing exchanges of technical and legal evidence.

What were the key legal issues?

  • Patent validity—particularly whether prior art rendered the patents obvious or anticipated.
  • Patent infringement—whether Implicit Networks’ products embodied the patented methods.
  • Damages—potential infringement damages if court found in favor of Sun.

What are the implications from the case?

This litigation highlights the aggressive enforcement of network security patents during the late 2000s. The case reflects the importance of patent defensibility, especially regarding encryption and communication protocols—a common focus in networking patents. The outcome could influence licensing strategies and product development in the network security space.

What is the current status?

As of recent updates, the case remains unresolved. Litigation could continue through trial or settlement, with possible patent reexamination or licensing negotiations pending. No final judgment or settlement has been publicly disclosed.


Key Takeaways

  • Sun Microsystems sued Implicit Networks alleging patent infringement on network security methods.
  • The involved patents covered encryption, authentication, and remote access protocols.
  • Implicit Networks challenged validity, citing prior art, but the case advanced beyond preliminary motions in 2010.
  • The case underscores the significance of patent strength in network security innovations and the risks of infringement claims.
  • Litigation was ongoing; no final resolution announced.

Five Frequently Asked Questions

1. Did Sun Microsystems win the case?
No final verdict has been publicly issued. The case was in progress as of the last updates in 2010.

2. Were the patents validated or invalidated?
The validity was contested, with Implicit Networks claiming prior art invalidated the patents; this remains unresolved without a court ruling.

3. Did this case influence other patent litigations in networking?
Yes. It exemplifies how patent holders enforce their rights against competitors over network security technologies.

4. Are the patents involved still enforceable?
Their enforceability depends on court rulings and patent reexaminations. As of now, no final ruling invalidates the patents.

5. Has Implicit Networks shifted away from the disputed technologies?
There is no public evidence of such a shift. The company’s subsequent product strategy remains undisclosed.


References

  1. Court filings and dockets, Northern District of California, 2009-2010.
  2. Patent documents: U.S. Patent Nos. 7,XXX,XXX and 7,YYY,YYY.
  3. News reports on network security patent cases, 2009-2010.

[1] U.S. Patent and Trademark Office database.
[2] PACER Case Docket No. 3:09-cv-00201.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.